Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Trends in Pharmacological Sciences Année : 2015

Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms

(1, 2) , (1, 2) , (1) , (1) , (1, 2) , (1, 2) , (1, 2)


Anticancer drugs continue to cause significant reductions in left ventricular ejection fraction resulting in congestive heart failure. The best-known cardiotoxic agents are anthracyclines such as doxorubicin. For several decades, cardiotoxicity was almost exclusively associated with anthracyclines, for which cumulative dose-related cardiac damage was the use-limiting step. Human epidermal growth factor receptor 2 (HER2; ErbB2) has been identified as an important target for breast cancer. Trastuzumab (TRZ), a humanized anti-HER2 monoclonal antibody, is currently recommended as first-line treatment for patients with metastatic HER2+ tumours. The use of TRZ may be limited by the development of drug intolerance, such as cardiac dysfunction. Cardiotoxicity has been attributed to free-iron-based, radical-induced oxidative stress. Many approaches have been promoted to minimize these serious side effects, but they are still clinically problematic. A new approach to personalized medicine for cancer that involves molecular screening for clinically relevant genomic alterations and genotype-targeted treatments is emerging.
Fichier principal
Vignette du fichier
TIPS-VERSION3-2015 final.pdf (951.31 Ko) Télécharger le fichier
Vignette du fichier
REVIEW-DOXO-TRASTU-TIPS-Figures -2015.pdf (1.21 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03434138 , version 1 (18-11-2021)



Luc Rochette, Charles Guenancia, Aurélie Gudjoncik, Olivier Hachet, Marianne Zeller, et al.. Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends in Pharmacological Sciences, 2015, 36 (6), pp.326-348. ⟨10.1016/⟩. ⟨hal-03434138⟩
15 Consultations
274 Téléchargements



Gmail Facebook Twitter LinkedIn More